An innovative approach for the characterization of the isoforms of a monoclonal antibody product

Protein biopharmaceuticals, such as monoclonal antibodies (mAbs) are widely used for the prevention and treatment of various diseases. The complex and lengthy upstream and downstream production methods of the antibodies make them susceptible to physical and chemical modifications. Several IgG1 immunoglobulins are used as medical agents for the treatment of colon, breast and head and neck cancers, and at least four to eight isoforms exist in the products. The regulatory agencies understand the complex nature of the antibody molecules and allow the manufactures to set their own specifications for lot release, provided the safety and efficacy of the products are established in animal models prior to clinical trials. During the manufacture of a mAb product, we observed lot-to-lot variability in the isoform content and, although the variability is within the set specifications for lot release, made attempts to gain mechanistic insight by isolating and characterizing the individual isoforms. Matrix-assisted laser desorption/ionization (MALDI) and liquid chromatography (LC)/mass spectrometry (MS)/MS analyses of the isolated isoforms indicate that this variability is caused by sialic acid content, as well as truncation of C-terminal lysine of the individual isoforms. Sialidase and carboxypeptidase treatment of the product confirm the observations made by MALDI and LC/MS/MS.Key words: IgG1, isoforms, charge heterogeneity, monoclonal antibody, glycosylation, silaic acidMonoclonal antibodies (mAbs) are used as medical agents to treat a variety of diseases including cancer, cardiovascular diseases and blood disorders.^1–3 Although a few IgG2 (e.g., panitumumab, denosumab) and IgG4 antibody molecules are in the market, most of the approved products are IgG1 molecules. IgG1 antibodies are glycoproteins with a conserved N-glycosylation site at Asn 297. Glycosylation influences the biological functions, such as antibody dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) of the antibodies. The oligosaccharides present in the IgG1 molecules are heterogeneous due to the presence of various sugar residues, including sialic acid, galactose, N-acetylglucasmine and fucose residues. Molecular alterations in antibodies can take place at every stage of manufacturing: upstream and downstream processing, formulation and storage. These alterations can take place enzymatically or non-enzymatically and may produce charge or size heterogeneity. Deamidation, proteolytic fragmentation, oxidation, disulfide bond shuffling and glycosylation are the most common modifications that occur during the production of protein therapeutics.^4–7 These modifications can reduce the biological activity and may induce immunogenicity in patients. Hence, the regulatory agencies require a comprehensive characterization of the structural integrity, purity and stability of the protein therapeutics.⁸To date, eight chimeric, humanized and human IgG1 mAbs have been approved in the United States, Europe, as well as other countries, for the treatment of several types of cancers.^9–12 One such molecule produced at ImClone has two N-glycosylation sites and at least six to eight isoforms with isoelectric points (pIs) between 7.9–8.9 are present in this product. Although techniques such as ion exchange chromatography (IEX) and capillary isoelectic focusing (IEF) are available for the separation and characterization of charge varients,^13,14 we were not successful in separating the individual isoforms with these techniques from the IgG1 product used in this investigation. The peaks from IEX showed the presence of multiple bands on IEF. Hence, an alternative approach was used to isolate each isoform of this IgG1 product, and we demonstrated the involvement of sialic acid and C-terminal lysine as the root causes for lot-to-lot variation observed during the production of this molecule. The method is fast and very effective in separating isoforms with a difference in the pI values < 0.1.